A compound of the general Formula I or pharmaceutically acceptable salts thereof, wherein: ring A is selected from rings A-1, A-2 and A-3 having the structures: wherein the wavy line labeled 1 indicates the point of attachment of ring A to ring B and the wavy line labeled 2 indicates the point of attachment of ring A to W; X is N or CH; Y is H or F; R 1 is H, alkoxy or halogen; ring B is selected from rings B-1 and B-2 having the structures: wherein the wavy line labeled 3 indicates the point of attachment to ring A and the wavy line labeled 4 indicates the point of attachment to the pyrazolo[1,5-a]pyrimidine ring of Formula I; W is O, NH or CH 2, wherein when ring A is A-2, then W is CH 2; m is 0, 1 or 2; D is carbon, R 2 and R 2a are independently H, F, (1-3 C)alkyl or OH (provided that R 2 and R 2a are not both OH), and R 3 and R 3a are independently H, (1-3 C)alkyl or hydroxy(1-3 C)alkyl, or D is carbon or nitrogen, R 2 and R 3 are absent, and R 2a and R 3a together with the atoms to which they are attached form a 5-6 membered heteroaryl ring having 1-2 ring heteroatoms; Z is *-NR 4a C(=O)-, *-ONHC(=O)-, *-NR 4b CH 2 - or *-OC(=O)-, wherein the asterisk indicates the point of attachment of Z to the carbon bearing R 3; R 4a is H, alkyl, fluoro alkyl, difluoro alkyl, trifluoro alkyl, hydroxy(1-6C alkyl) or dihydroxy(2-6C alkyl); R 4b is H, alkyl, fluoro alkyl, difluoro alkyl, trifluoro alkyl, hydroxy(1-6C alkyl), dihydroxy(2-6C alkyl), (1-6C alkyl)C -, (3-6C cycloalkyl)C -, Ar 1 C -, HOCH 2 C -, (1-6C alkyl)sulfonyl, (3-6C cycloalkyl)sulfonyl, Ar 2 (SO 2)-, HO 2 CCH 2 - or (1-6C alkyl)NH -; Ar 1 is phenyl optionally substituted with one or more substituents independently selected from halogen, alkyl, and alkoxy; Ar 2 is phenyl optionally substituted with one or more substituents independently selected from halogen, alkyl, and alkoxy; and R 5 and R 6 are independently H, halogen, OH, alkyl or hydroxy alkyl. ring A is selected from rings A-1, A-2 and A-3 having the structures: wherein the wavy line labeled 1 indicates the point of attachment of ring A to ring B and the wavy line labeled 2 indicates the point of attachment of ring A to W; X is N or CH; Y is H or F; R 1 is H, alkoxy or halogen; ring B is selected from rings B-1 and B-2 having the structures: wherein the wavy line labeled 3 indicates the point of attachment to ring A and the wavy line labeled 4 indicates the point of attachment to the pyrazolo[1,5-a]pyrimidine ring of Formula I; W is O, NH or CH 2, wherein when ring A is A-2, then W is CH 2; m is 0, 1 or 2; D is carbon, R 2 and R 2a are independently H, F, (1-3 C)alkyl or OH (provided that R 2 and R 2a are not both OH), and R 3 and R 3a are independently H, (1-3 C)alkyl or hydroxy(1-3 C)alkyl, or D is carbon or nitrogen, R 2 and R 3 are absent, and R 2a and R 3a together with the atoms to which they are attached form a 5-6 membered heteroaryl ring having 1-2 ring heteroatoms; Z is *-NR 4a C(=O)-, *-ONHC(=O)-, *-NR 4b CH 2 - or *-OC(=O)-, wherein the asterisk indicates the point of attachment of Z to the carbon bearing R 3; R 4a is H, alkyl, fluoro alkyl, difluoro alkyl, trifluoro alkyl, hydroxy(1-6C alkyl) or dihydroxy(2-6C alkyl); R 4b is H, alkyl, fluoro alkyl, difluoro alkyl, trifluoro alkyl, hydroxy(1-6C alkyl), dihydroxy(2-6C alkyl), (1-6C alkyl)C -, (3-6C cycloalkyl)C -, Ar 1 C -, HOCH 2 C -, (1-6C alkyl)sulfonyl, (3-6C cycloalkyl)sulfonyl, Ar 2 (SO 2)-, HO 2 CCH 2 - or (1-6C alkyl)NH -; Ar 1 is phenyl optionally substituted with one or more substituents independently selected from halogen, alkyl, and alkoxy; Ar 2 is phenyl optionally substituted with one or more substituents independently selected from halogen, alkyl, and alkoxy; and R 5 and R 6 are independently H, halogen, OH, alkyl or hydroxy alkyl.